纤维化是许多器官靶向疾病的常见特征，全世界范围内组织纤维化是许多疾病致残、致死的主要原因之一。纤维化的发病机制复杂，涉及细胞因子、信号通道和基因表达等。这些机制的相互作用导致细胞外基质过度积累，最终取代并破坏生理器官结构和功能。针对发病机制，临床虽然应用了一些抗纤维化的药物，但仍未达到满意的治疗效果。因此寻找一种高效低毒的抗纤维化药物一直是临床的迫切需要。人参皂苷（ginsenosides）是从人参Panax ginseng中发现的一类糖基化三萜类天然产物，具有抗氧化、抗炎、抗纤维化和抗肿瘤等作用。归纳人参皂苷抗器官纤维化的药理作用及其机制研究进展，以期为此类化合物的抗纤维化的成药性研究提供理论依据。

Fibrosis is a common feature of many organ-targeted diseases, and it is one of the major causes of disability and death from many diseases worldwide. The pathogenesis of fibrosis is complex, involving cytokines, signal channels and gene expression. The interaction of these mechanisms leads to the excessive accumulation of extracellular matrix, which eventually replaces and destroys the structure of physiological organs. According to the pathogenesis, although some antifibrosis drugs have been used in clinic, they have not achieved satisfactory therapeutic effect. Therefore, it is an urgent need to find an effective and low toxicity antifibrosis drug. Ginsenosides are a group of glycosylated triterpenoids found in Renshen (Panax ginseng), which has anti-oxidant, anti-inflammatory, antifibrosis and antitumor effects. This essay summarizes the research progress on pharmacological effects and mechanism of ginsenosides on organ fibrosis in order to provide a theoretical basis for the study of the antifibrosis properties of these compounds.

R285

国家自然科学基金青年基金项目(81703386);沈阳药科大学骨干人才培养计划项目(ZQN2018003);辽宁省民生科技计划项目(2021JH2/10300074)